(Total Views: 442)
Posted On: 11/04/2024 8:51:07 AM
Post# of 148854
So we know what we will be studying:
The study will evaluate the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer (“CRC”).
Investors Hangout: https://investorshangout.com/post/view?id=672...z8qcVP9Guq
What else do we know besides beginning enrollment timeframe?
The study will evaluate the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer (“CRC”).
Investors Hangout: https://investorshangout.com/post/view?id=672...z8qcVP9Guq
What else do we know besides beginning enrollment timeframe?
(1)
(0)Scroll down for more posts ▼
